what is the difference between a glp 1 and semaglutide GLP-1 Same as Ozempic? The GLP-1 Powerhouses: Semaglutide vs.

Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists

is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264

On one hand, pro-inflammatory immune cells (e.g., M1-type macrophages, Th17 cells) directly or indirectly contribute to cartilage degeneration and extracellular matrix degradation by releasing inflammatory factors (e.g., TNF-, IL-1, IL-6) and matrix-degrading enzymes (e.g., MMPs, ADAMTS)

2023 Aug